iA Global Asset Management Inc. Buys 3,110 Shares of Exact Sciences Co. (NASDAQ:EXAS)

iA Global Asset Management Inc. boosted its stake in Exact Sciences Co. (NASDAQ:EXAS) by 4.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 72,752 shares of the medical research company’s stock after acquiring an additional 3,110 shares during the period. iA Global Asset Management Inc.’s holdings in Exact Sciences were worth $4,088,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in EXAS. RPg Family Wealth Advisory LLC bought a new stake in shares of Exact Sciences during the 3rd quarter valued at $34,000. Asset Planning Inc bought a new stake in shares of Exact Sciences during the 4th quarter valued at $40,000. Modus Advisors LLC bought a new stake in shares of Exact Sciences during the 4th quarter valued at $43,000. AlphaQuest LLC boosted its holdings in shares of Exact Sciences by 22,825.0% during the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company’s stock valued at $52,000 after buying an additional 913 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in shares of Exact Sciences during the 4th quarter valued at $66,000. Institutional investors own 88.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on EXAS. Bank of America dropped their target price on shares of Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a report on Thursday, February 20th. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 20th. Benchmark reaffirmed a “buy” rating and issued a $65.00 price target on shares of Exact Sciences in a research report on Monday, January 13th. BTIG Research lifted their price target on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Finally, Piper Sandler lowered their price target on Exact Sciences from $75.00 to $70.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Exact Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $70.83.

Exact Sciences Trading Down 3.1 %

Exact Sciences stock opened at $44.28 on Friday. The business has a 50-day simple moving average of $50.77 and a two-hundred day simple moving average of $58.39. The company has a market cap of $8.23 billion, a P/E ratio of -7.95 and a beta of 1.25. Exact Sciences Co. has a 52-week low of $40.62 and a 52-week high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23. The business had revenue of $713.42 million during the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. Analysts predict that Exact Sciences Co. will post -0.58 EPS for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.